Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Rectal Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Nivolumab 32Bevacizumab 13Sunitinib 10Ipilimumab 10aldesleukin 7Interleukin-2 7Axitinib 7lenvatinib 6cabozantinib 6Paclitaxel 6Everolimus 6Docetaxel 6Cyclosporine 6Cyclophosphamide 6fludarabine phosphate 5Sorafenib 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4cemiplimab 4belzutifan 4Whole-Body Irradiation 4Radiosurgery 4Interferon-alpha 4Cetuximab 4durvalumab 3bempegaldesleukin 3avelumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Renal Cell × etaracizumab × Clear all
NCT00684996 2014-05-15

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡